ALS treatment pipeline, worth a read highlighted some key points below:
I have considered that the high rate of ALS treatment failures is due to the sporadic nature of ALS. Therefore, for a treatment to succeed it would need to be selectivity without off-target side effects. We know Monepantel has a high safety profile. Also the most recent HEALY platform regimens are both focused on TDP43 inhibition. Take this as a sign that the specialists agree this is an area of focus.
This bodes well for Monepantel, as an activator of Autophagy (natural cleansing process for protein aggregation), mTor inhibition (anti-inflammatory) and its downstream target (preventing TDP-43 aggregation along with other proteins linked to ALS).
Also, as highlighted by Pharmaust and many here, Monepantel has the potential to translate to other neurodegenerative disorders. Preclinicals inbound - Watch this Space!
Selective ALS Targets
Lots of downstream targets but TDP43, mtor and autophagy closer to the top of the list - interesting how does this sit with Monepantal?
READ ME - ALS PIPELINE!
Source: 14728214.2024.2333420 (tandfonline.com)
Healy Platform Trials (status)
Source:
1Study Drugs in the HEALEY ALS Platform Trial (massgeneral.org)2Zilucoplan Arm in HEALEY Trial for ALS Stopped Early for Lack of Benefit (alsnewstoday.com)3Biohaven Provides Update From Pivotal Phase 2/3 Trial with Verdiperstat in Amyotrophic Lateral Sclerosis (Healy ALS Platform Trial) (prnewswire.com)4Healey & AMG Center announces top line results in ALS platform trial with CMN-Au8 (massgeneral.org)5Phase 3 clinical trial of pridopidine in ALS patients likely this year (alsnewstoday.com)
- Forums
- ASX - By Stock
- Ann: PharmAust Presentation
ALS treatment pipeline, worth a read highlighted some key points...
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $77.20M |
Open | High | Low | Value | Volume |
19.5¢ | 19.5¢ | 18.8¢ | $342.8K | 1.779M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 52999 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 421000 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 52999 | 0.195 |
12 | 701109 | 0.190 |
8 | 303874 | 0.185 |
11 | 266915 | 0.180 |
7 | 654521 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 421000 | 3 |
0.205 | 105141 | 6 |
0.210 | 300000 | 2 |
0.215 | 507775 | 7 |
0.220 | 239679 | 2 |
Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |